The Global Immunocell Therapy Market was valued at USD 1.88 Billion in 2023 and is projected to reach USD 5.64 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 13.0% during the forecast period (2023-2032). This remarkable growth is fueled by rising cancer incidence rates, breakthrough innovations in cellular engineering, and increasing clinical adoption of immunotherapy as standard cancer care.
As precision medicine transforms oncology treatment paradigms, biopharmaceutical companies are advancing cutting-edge immunocell therapies with unprecedented clinical results. This analysis profiles the Top 10 Companies in the Immunocell Therapy Industry—both established pharmaceutical leaders and emerging biotech innovators driving the cellular immunotherapy revolution.
🔟 1. Novartis AG
Headquarters: Basel, Switzerland
Key Product: Kymriah® (tisagenlecleucel) – first FDA-approved CAR-T cell therapy
Novartis pioneered the commercial CAR-T therapy market with Kymriah, approved for multiple hematologic malignancies. The company operates global manufacturing facilities and maintains one of the most advanced immunocell therapy pipelines in the industry.
Therapeutic Advancements:
- First-to-market with FDA-approved CAR-T therapy (2017)
- Developing next-generation allogeneic (off-the-shelf) T-cell platforms
- Strategic collaborations with leading academic medical centers
Download FREE Sample Report:
Immunocell Therapy Market – View in Detailed Research Report
9️⃣ 2. Gilead Sciences (Kite Pharma)
Headquarters: Santa Monica, California, USA
Key Products: Yescarta® (axicabtagene ciloleucel), Tecartus® (brexucabtagene autoleucel)
Gilead’s Kite Pharma subsidiary dominates the autologous CAR-T therapy space with two approved treatments for lymphoma and leukemia. Their commercial infrastructure supports treatment delivery across North America and Europe.
Therapeutic Advancements:
- First CAR-T therapy approved for indolent non-Hodgkin lymphoma
- Pioneering rapid manufacturing processes (under 7 days)
- Expanding into solid tumor applications
8️⃣ 3. Bristol-Myers Squibb
Headquarters: New York, USA
Key Products: Breyanzi® (lisocabtagene maraleucel), Abecma® (idecabtagene vicleucel)
BMS emerged as a cell therapy leader through strategic acquisitions and internal development. The company’s two FDA-approved CAR-T therapies target different hematologic malignancies with distinct mechanisms of action.
Therapeutic Advancements:
- First CAR-T therapy approved for multiple myeloma (Abecma)
- Proprietary manufacturing processes ensuring consistent product quality
- Exploring combination therapy approaches with checkpoint inhibitors
7️⃣ 4. Johnson & Johnson (Legend Biotech)
Headquarters: New Brunswick, New Jersey, USA
Key Product: Carvykti™ (ciltacabtagene autoleucel)
Through its collaboration with Legend Biotech, J&J commercializes Carvykti, a BCMA-targeted CAR-T therapy for multiple myeloma. The company is rapidly expanding its cell therapy portfolio through strategic partnerships and acquisitions.
Therapeutic Advancements:
- Novel targets for hematologic malignancies
- Global commercialization infrastructure and capabilities
- Automated manufacturing platforms reducing production variability
6️⃣ 5. JW Therapeutics
Headquarters: Shanghai, China
Key Product: Relma-cel (relmacabtagene autoleucel)
As China’s leading cell therapy company, JW Therapeutics developed the country’s first domestically approved CAR-T product. The company combines global innovation with localized manufacturing capabilities.
Therapeutic Advancements:
- First China-approved CAR-T therapy (2021)
- Cost-optimized manufacturing solutions for emerging markets
- Clinical programs specifically addressing Asian patient populations
Download FREE Sample Report:
Immunocell Therapy Market – View in Detailed Research Report
5️⃣ 6. FOSUNKite
Headquarters: Shanghai, China
Key Product: FKC876 (axicabtagene ciloleucel)
This Fosun Pharma-Kite Pharma joint venture brings CAR-T technology to China. FOSUNKite has successfully localized Yescarta (FKC876) for the Chinese market while developing additional cellular therapies.
Therapeutic Advancements:
- Established distribution network across China
- Localized manufacturing and regulatory strategies
- Expanding treatment access in Asia-Pacific markets
4️⃣ 7. CARsgen Therapeutics
Headquarters: Shanghai, China
Key Pipeline: CT053 (BCMA CAR-T), CT041 (CLDN18.2 CAR-T)
CARsgen is advancing an innovative pipeline of CAR-T therapies targeting both blood cancers and solid tumors. The company has established clinical trials in China, the U.S., and Canada.
Therapeutic Advancements:
- Promising solid tumor CAR-T candidates in development
- Next-generation CAR constructs with enhanced functionality
- Proprietary manufacturing technologies improving product consistency
3️⃣ 8. Autolus Therapeutics
Headquarters: London, UK
Key Pipeline: Obe-cel (obecabtagene autoleucel)
This UK biotechnology company is developing next-generation CAR-T therapies incorporating proprietary safety switches. Their platforms aim to improve efficacy while reducing treatment-related toxicities.
Therapeutic Advancements:
- Controlled CAR-T activation technology reducing side effects
- Novel targeting strategies potentially enabling solid tumor approaches
- Clinical-stage programs in B-cell malignancies
2️⃣ 9. Mustang Bio
Headquarters: Worcester, Massachusetts, USA
Key Pipeline: MB-106 (CD20-targeted CAR-T)
Mustang Bio is progressing a promising CAR-T pipeline focused on hematologic malignancies. The company is developing both autologous and allogeneic approaches to expand treatment accessibility.
Therapeutic Advancements:
- Novel targets for B-cell malignancies
- Developing off-the-shelf CAR-NK cell therapy programs
- Scalable manufacturing platforms supporting clinical expansion
1️⃣ 10. Bluebird Bio
Headquarters: Somerville, Massachusetts, USA
Key Contribution: Abecma® (in partnership with BMS)
While primarily focused on gene therapy, Bluebird Bio made significant contributions to cell therapy through its collaboration on Abecma. The company continues cellular immunotherapy research alongside its gene therapy programs.
Therapeutic Advancements:
- Key role in developing the first CAR-T for multiple myeloma
- Advancing next-generation gene-edited cell therapies
- Innovative research in immune cell engineering techniques
Get Full Report Here:
Immunocell Therapy Market – View in Detailed Research Report
🌍 The Future of Immunocell Therapy
The immunocell therapy field continues to evolve rapidly, with companies developing innovative solutions to improve efficacy, accessibility, and safety. While autologous CAR-T therapies currently dominate, next-generation approaches are transforming the treatment landscape.
📈 Key Market Trends:
- Shift from autologous to allogeneic (off-the-shelf) therapies
- Expansion into solid tumor indications
- Development of combination treatment regimens
- Advancements in manufacturing efficiency and scalability
- Emergence of engineered immune cells beyond T cells (NK cells, macrophages)
Market Challenges and Opportunities
- Cost reduction strategies – Innovations in manufacturing to improve affordability
- Enhanced safety profiles – Next-gen constructs reducing severe adverse events
- Global access expansion – Regional manufacturing networks in Asia and Europe
- Regulatory harmonization – Alignment of approval pathways across major markets
Get Full Report Here:
Immunocell Therapy Market – View in Detailed Research Report
The companies profiled represent the vanguard of immunocell therapy innovation, each contributing unique capabilities to advance cancer treatment. As the field matures, these industry leaders are addressing critical challenges while expanding the potential of cellular medicine to transform patient outcomes.